CureVac N.V. (Nasdaq: CVAC), a pioneering multinational biotech company developing a new class of transformative medicines based on messenger RNA (mRNA), today announced that CureVac N.V. and an affil...
Tumors of the pancreas seldom cause symptoms in their early stages. This means that in many cases, they are not diagnosed until late, when the chances of successful treatment are poor. A new non-invasive diagnostic method designed by Fraunhofer ...
Our joint application in the ERDF funding call for strengthening regional innovation systems through cluster initiatives has been approved. On July 22, 2025, we were offi...
On July 17, 2025, our joint Summer Reception took place at the Tübingen-Reutlingen Technology Park – an inspiring event full of lively conversations, exciting insights, and celebratory highlights. Together with TTR GmbH and the Association for t...
Study led by the University of Tübingen: many non-antibiotics weaken the natural protective function of the intestine – with consequences for the colonization with pathog...
On July 9, 2025, the Baden-Württemberg Savings Banks Association presented the Founders Award for the 27th time. Since 1997, the association has honored start-ups that inspire with a compelling busine...
On June 27, 2025, the closing event of the SustainMed funding project took place at the Ministry of the Interior, for Digitization and Municipalities in Stuttgart. The event, organized by BioRegio STE...
On June 25, 2025, the workshop “Incisions – Insights: Sustainability in the OR | Green Hospital” was held once again at the Institute of Clinical Anatomy at the University of Tübingen. This created a ...
CureVac N.V. (Nasdaq: CVAC), a pioneering multinational biotech company developing a new class of transformative medicines based on messenger RNA (mRNA), today announced the voting results of the Comp...
Acquisition will strengthen the research, development, manufacturing and commercialization of mRNA-based cancer immunotherapy candidates, marking BioNTech’s next key mile...
On June 4 and 5, 2025, we had the opportunity to participate in two outstanding events that focused on the innovative SME sector in Germany and highlighted the central ro...
Yesterday, BioRegio STERN Management GmbH, together with LBBW Venture Capital GmbH, once again invited to Viewpoint Biotech 2025 in Tübingen. Start-ups, entrepreneurs, and industry experts came together to exchange ideas about current developmen...
Stafford, Texas and Tuebingen, Germany, May 31, 2025 – Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), a clinical-stage biopharmaceutical company active in the...
TÜBINGEN, Germany/BOSTON, USA – May 15, 2025CureVac N.V. (Nasdaq: CVAC) (“CureVac”), a global biotech company developing a new class of transformative medicines based on...
Houston, Texas and Tuebingen, Germany, May 13, 2025 – Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), a clinical-stage biopharmaceutical company active in the ...
05/13/2025
| Council of European BioRegions (CEBR)
The Council of European BioRegions (CEBR), the leading network of life science clusters across Europe, is pleased to announce the results of its 2025–2026 Board Elections...
On May 9, 2025, representatives from the life sciences industry in North Carolina and Baden-Württemberg met in Stuttgart for professional exchange. The goal of the event was to explore opportunities f...
Researchers at the University of Stuttgart have used microbial processes to produce environmentally friendly bio-concrete from urine as part of a “wastewater-bio-concrete-fertilizer” value chain. With the project extension granted by the Baden-W...
Tuebingen, Germany, April 15, 2025 – HepaRegeniX GmbH (“HepaRegeniX”), a clinical-stage company advancing novel therapies to treat acute and chronic liver diseases, today...
